NeuroMetrix (NASDAQ:NURO) Research Coverage Started at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research note issued on Wednesday. The firm set a “sell” rating on the medical device company’s stock.

NeuroMetrix Stock Performance

Shares of NURO stock opened at $3.89 on Wednesday. NeuroMetrix has a 52-week low of $2.66 and a 52-week high of $5.96. The stock has a market cap of $7.82 million, a price-to-earnings ratio of -0.62 and a beta of 2.28. The firm’s 50-day moving average is $3.63 and its 200-day moving average is $3.84.

NeuroMetrix (NASDAQ:NURO) last issued its earnings results on Tuesday, August 6th. The medical device company reported ($0.74) EPS for the quarter. NeuroMetrix had a negative return on equity of 41.74% and a negative net margin of 181.04%. The business had revenue of $0.77 million for the quarter.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.